S&P 500 7,431.46 +0.50% NASDAQ 25,888.84 +0.31% DOW 51,202.26 +0.70% R2K 2,943.99 +0.79% VIX 17.68 -9.05% US 10Y 4.49 +0.54% DXY 99.75 -0.11% GOLD 4,215.00 +3.05% CRUDE 84.88 -3.23% BITCOIN 63,800.00 +0.40%
Next Bullish Trade
BMY Bristol-Myers Squibb Company NYQ
$57.13 +0.23 (+0.40%)
Neutral · +0.26σ
+ Compare Set alert Open in Sniper

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $11.5B $2.7B $3.4B $0.8B 23.3% 29.3%
2025-12-31 $12.5B $1.1B $2.8B $1.6B 8.7% 22.5%
2025-09-30 $12.2B $2.2B $3.6B $6.0B 18.0% 29.8%
2025-06-30 $12.3B $1.3B $3.8B $3.6B 10.7% 30.8%
2025-03-31 $11.2B $2.5B $3.5B $1.7B 21.9% 31.2%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%
2024-09-30 $nanB $nanB $nanB $nanB nan% nan%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-04-30 1.58 1.42 +11.2%
2026-02-05 0.53 0.98 -45.7%
2025-10-30 1.08 1.04 +3.4%
2025-07-31 1.46 1.10 +32.6%
2025-04-24 1.80 1.50 +19.9%
2025-02-06 0.04 0.90 -95.6%
2024-10-31 1.80 1.50 +20.0%
2024-07-26 2.07 1.63 +27.4%
2024-04-25 -4.40 -4.40 -0.1%
2024-02-02 1.70 1.58 +7.8%
2023-10-26 0.93 0.89 +4.0%
2023-07-27 1.75 1.99 -12.0%
2023-04-27 2.05 1.97 +3.9%
2023-02-02 1.82 1.73 +5.2%
2022-10-25 1.99 1.83 +8.5%
2022-07-27 1.93 1.80 +7.3%
2022-04-29 1.96 1.90 +3.3%
2022-02-04 1.83 1.80 +1.7%
2021-10-27 2.00 1.92 +4.3%
2021-07-28 1.93 1.90 +1.8%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
BMY ★ $117B 16.0 9.3 2.4 8.0 5.8 72.0% 2.6% 9.2% 8.44%
LLY $1,010B 40.3 25.5 14.0 28.9 32.4 82.8% 55.5% 169.9% 0.91%
UNH $371B 30.8 19.5 0.8 19.8 3.8 18.8% 2.0% 0.7% 4.77%
JNJ $580B 27.9 18.9 6.0 17.9 7.1 68.0% 9.9% -52.9% 2.16%
MRK $294B 33.5 12.4 4.5 11.4 6.4 76.7% 4.9% — 4.78%
ABBV $402B 111.1 14.0 6.4 15.6 -60.5 72.0% 12.4% -46.2% 5.17%
PFE $149B 20.0 9.3 2.4 7.9 1.7 74.8% 5.4% -10.1% 8.29%
TMO $174B 25.8 17.2 3.9 19.0 3.3 40.9% 6.2% 11.3% 3.17%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 36.69%

HolderShares% out
Blackrock Inc. 171,682,888 8.41%
Vanguard Capital Management LLC 132,320,240 6.48%
State Street Corporation 98,564,914 4.83%
JPMORGAN CHASE & CO 92,475,194 4.53%
Charles Schwab Investment Management 61,115,373 2.99%
Geode Capital Management, LLC 55,286,174 2.71%
Vanguard Portfolio Management LLC 46,230,155 2.26%
Bank of America Corporation 32,586,981 1.60%
AQR Capital Management, LLC 29,631,105 1.45%
Morgan Stanley 29,198,554 1.43%

Insider activity · 90d

3 buys / 2 sells · ratio 1.5 · Finnhub

  • Short Bartie Wendy M 8,040
  • Short Bartie Wendy F 12,081 @ $54.72
  • Short Bartie Wendy M 15,957
  • Lenkowsky Adam M 1,375
  • Lenkowsky Adam F 19,706 @ $58.22
  • Lenkowsky Adam J 20,305
  • Lenkowsky Adam M 20,508
  • Shanahan Karin M 0
  • Shanahan Karin F 25,888 @ $61.73
  • Shanahan Karin M 27,580

Analyst estimates

Finnhub
Low
$40.0
Mean
$63.08
High
$75.0
Analysts
25
Recommendation distribution · period 2026-06-01
6
8
20
2
Revision trend (2026-03-01 → 2026-06-01): net 13 → 12 -1 (net = strong_buy+buy − sell−strong_sell)

SEC filings

FormFiled DescriptionAction
4 2026-06-05 FORM 4 view ·
8-K 2026-05-08 CURRENT REPORT view ·
4 2026-05-05 FORM 4 view ·
10-Q 2026-04-30 10-Q view ·
8-K 2026-04-30 8-K view ·
4 2026-04-02 FORM 4 view ·
4 2026-04-02 FORM 4 view ·
4 2026-04-02 FORM 4 view ·
4 2026-04-02 FORM 4 view ·
4 2026-04-02 FORM 4 view ·
4 2026-04-02 FORM 4 view ·
4 2026-04-02 FORM 4 view ·
DEF 14A 2026-03-25 DEF 14A view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-03 FORM 4 view ·
10-K 2026-02-11 10-K view ·
8-K 2026-02-05 8-K view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
8-K 2026-01-12 CURRENT REPORT view ·
4 2026-01-05 FORM 4 view ·
4 2026-01-05 FORM 4 view ·
4 2026-01-05 FORM 4 view ·
4 2026-01-05 FORM 4 view ·
4 2026-01-05 FORM 4 view ·
8-K 2025-11-18 CURRENT REPORT view ·
8-K 2025-11-10 FORM 8-K view ·
4 2025-11-04 FORM 4 view ·
4 2025-11-04 FORM 4 view ·
4 2025-11-04 FORM 4 view ·
4 2025-11-04 FORM 4 view ·
8-K 2025-11-03 CURRENT REPORT view ·
10-Q 2025-10-30 10-Q view ·
8-K 2025-10-30 8-K view ·
4 2025-10-06 FORM 4 view ·
4 2025-10-02 FORM 4 view ·
4 2025-10-02 FORM 4 view ·

About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT…